Design Therapeutics, Inc.
NASDAQ:DSGNBiotechnology
Healthcare
$9.47 +1.59%
+$0.19 today
- Market cap
- $606.42M
- Beta
- 1.66
- P/E (TTM)
- -10.7
- EPS (TTM)
- -$1.13
52W Low $3.33High $17.25
Volume 0.32M
Average 0.74M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$79.47M
FY 2025 · Annual
Net Income
-$69.79M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 466K | 537K | 596K | 622K |
| Gross Profit | 0 | (466K) | (537K) | (596K) | (622K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 24.78M | 48.61M | 57.06M | 44.35M | 59.13M |
| Selling, General & Admin | 11.05M | 18.98M | 21.13M | 18.03M | 20.34M |
| Operating Expenses | 35.83M | 67.13M | 77.65M | 61.79M | 78.85M |
| Depreciation & Amortization | 129K | 466K | 537K | 596K | 622K |
| EBITDA | (35.4M) | (62.84M) | (66.33M) | (48.99M) | (69.17M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (35.83M) | (67.59M) | (78.19M) | (62.38M) | (79.47M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 12.8M | 9.68M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 298K | 4.29M | 11.33M | 12.8M | 9.68M |
| Income Before Tax | (35.53M) | (63.31M) | (66.86M) | (49.59M) | (69.79M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (35.53M) | (63.31M) | (66.86M) | (49.59M) | (69.79M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.77) | (1.14) | (1.19) | (0.88) | (1.22) |
| EPS (Diluted) | (0.77) | (1.14) | (1.19) | (0.88) | (1.22) |
| 45.94M | 55.71M | 55.98M | 56.59M | 57.33M | |
| 45.94M | 55.71M | 55.98M | 56.59M | 57.33M |
DSGN Earnings Waterfall · TTM
NASDAQ:DSGN · Revenue to Net Income
Key Ratios
EPS$-1.20
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-6.6
P/S Ratio0.0
Analysis
$0 of revenue converted into -$69.7M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.20, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| EFFECT | EFFECT filing | Nov 12, 2026 | |
| 424B5 | 424B5 filing | Nov 4, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 8-K | Current report | Nov 4, 2026 | |
| S-3 | S-3 filing | Nov 4, 2026 |
How much revenue does DSGN generate?
Design Therapeutics, Inc. (DSGN) reported $0.00 of revenue in fiscal 2025.
Is DSGN profitable?
Design Therapeutics, Inc. (DSGN) reported -$69.79M of net income.
Continue the stock analysis
Jump to another research area for this company.